Microphysiological systems for modeling autoimmunity in type 1 diabetes

用于模拟 1 型糖尿病自身免疫的微生理系统

• 批准号: 10453212
• 负责人: PAUL J GADUE
• 金额: $ 112.66万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-02 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10453212
• 关键词: Microphysiological; systems; modeling; autoimmunity; type

SUMMARY This proposal leverages our group’s complementary expertise in tissue-on-a-chip technology, immunology, pluripotent cell derivation and differentiation, and islet biology to create robust systems containing human islet cells, immune cells, and other features to recapitulate the process of islet autoimmunity in type I diabetes (T1D). The UG3 phase of this proposal will improve upon already-robust microdevices and develop new cell lines and assays that will enable studies of autoimmunity in an isogenic setting. The UH3 phase of this proposal will exploit these tools and platforms to develop isogenic models that can be used to study immune-islet interactions. The focus of the UH3 phase will be to investigate the determinants of islet infiltration and killing, and to determine the effects of mutations in T1D-associated genes on this process. In addition, these in vitro systems will be used to pilot the use of cellular therapies to interrupt the autoimmune attack of islets. The specific aims of the UG3 phase are: Aim 1: To expand the biomimetic platform Aim 2: To develop models of T cell-mediated autoimmunity Aim 3: To establish new iPSC lines and novel reporters of b cell stress and death The specific aims of the UH3 phase are: Aim 1: To develop isogenic models of autoimmune T1D Aim 2: To identify determinants of islet infiltration and immune killing Aim 3: To perform genetic studies of autoimmunity in T1D

摘要 这项建议充分利用了我们团队在芯片组织技术、免疫学、 多能细胞的衍生和分化，以及创建包含人胰岛的强大系统的胰岛生物学 细胞、免疫细胞和其他特征，以概括I型糖尿病(T1D)的胰岛自身免疫过程。 这项提案的UG3阶段将在已经强大的微型设备的基础上改进，并开发新的细胞系和 这将使在等基因环境下进行自身免疫研究成为可能。该提案的UH3阶段将利用 这些工具和平台用于开发可用于研究免疫-胰岛相互作用的等基因模型。这个 UH3阶段的重点将是调查胰岛渗透和杀伤的决定因素，并确定 T1D相关基因突变对这一过程的影响。此外，这些体外系统将被用于 试点使用细胞疗法来阻断胰岛的自身免疫攻击。 普遍定期审议第三阶段的具体目标是： 目标1：拓展仿生平台 目的2：建立T细胞介导的自身免疫模型 目的3：建立新的ipsc系和新的b细胞应激和死亡报告 UH3阶段的具体目标是： 目的1：建立自身免疫性T1D等基因动物模型 目的2：确定胰岛浸润和免疫杀伤的决定因素 目的3：进行T1D自身免疫的遗传学研究